Stem Cell Caution
By Richard Hayes,
Tom Paine
| 05. 24. 2006
Support for stem cell research has become a cause célèbre among Democrats. Last year New Jersey Senator Jon Corzine made it a big part of his successful campaign for Governor. This year New York Attorney General Elliott Spitzer is proposing a $1 billion stem cell bond issue as part of his own gubernatorial campaign. In Missouri Democrat Claire McCaskill is spotlighting stem cell research in her effort to unseat Republican Senator Jim Talent. And this week marks the one year anniversary of the passage of Castle-DeGette, the House bill that expands federal funding for stem cell research. Senate Democrats are rallying to push for a vote as soon as possible on the Senate version of this bill.
I'm a life-long liberal Democrat, pro-choice on abortion and a supporter of innovative medical research. I believe that stem cell research holds promise, and that the Bush administration's policies are unnecessarily restrictive. Now stem cells appear to be giving Democrats a potent vote-getting wedge issue.
Why am I worried about this?
I'm worried because in their over-the-top enthusiasm for stem cell and cloning...
Related Articles
By Carly Mallenbaum, Axios [cites Emily Galpern] | 03.29.2026
More Americans are turning to surrogacy to build their families, as the practice becomes more common and more publicly discussed.
Why it matters: As surrogacy becomes more visible and accessible, ethical, legal and cultural tensions become harder to ignore...
By Carly Mallenbaum, Axios [cites Surrogacy360] | 03.29.2026
Without a federal law, surrogacy in the U.S. is governed by a patchwork of state regulations/
Why it matters: Confusing, varied local rules can determine everything from whether agreements are legally binding to who is recognized as a parent at...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
